LNSRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
LENSAR, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$5.75−0.05 (-0.86%)
Close on Oct 19, 2026
- Market cap
- $132.41M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
46.4%−6.9 pts over 5 years
Operating margin
-42.1%+28.1 pts over 5 years
Net margin
-58.7%+16.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +9.2% | +18.2% | +17.2% | – | |
| Gross profit | +4.9% | +10.8% | +14.0% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -107.9% | 324.1% | |
| Return on assets | – | -34.8% | -49.8% | |
| Current ratio | – | 6.90 | 1.15 | |
| Interest coverage | – | -13.8× | – | |
| Inventory turnover | – | 1.1× | 1.9× | |
| Capex to revenue | – | 1.4% | 0.1% | |
| Diluted shares | – | 5M | 12M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Lensar generated $50.59M from operations and spent $944.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$50.59M
Used
$944.00K
Capital expenditure$944.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-58.7%
×Asset turnover0.85×
×Equity multiplier-6.51×
=Return on equity, FY2025324.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -58.7% | 0.85× | -6.51× | 324.1% |
| FY2024 | -58.7% | 0.79× | 3.55× | -164.0% |
| FY2023 | -34.1% | 0.67× | 1.66× | -38.1% |
| FY2022 | -56.3% | 0.58× | 1.26× | -41.1% |
| FY2021 | -56.9% | 0.47× | 1.19× | -32.1% |
| FY2020 | -75.0% | 0.46× | 3.10× | -107.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$34.28M
- Cash generatingOperating cash flow above zero-$14.83M
- Return on assets improvedROA up on the prior year-45.1% → -51.7%
- Earnings backed by cashOperating cash flow above net income-$14.83M vs -$34.28M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.80 → 1.15
- No dilutionShare count did not rise12M → 12M
- Gross margin improvedGross margin up on the prior year48.33% → 46.41%
- More efficientAsset turnover rose0.77 → 0.88